Drug Profile
Research programme: MMP inhibitors - Millennium
Alternative Names: Matrix metalloprotease inhibitors research programme - Millennium; Matrix metalloproteinase inhibitors research programme - Millennium; MMP inhibitors research programme - Millennium; Research programme: matrix metalloprotease inhibitors - Millennium; Research programme: matrix metalloproteinase inhibitors - MillenniumLatest Information Update: 29 Nov 2005
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Class
- Mechanism of Action Matrix metalloproteinase inhibitors; Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Cardiovascular disorders; Inflammation
Most Recent Events
- 29 Nov 2005 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 29 Nov 2005 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 29 Nov 2005 Discontinued - Preclinical for Inflammation in USA (unspecified route)